Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to acquire ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

A study identifies promising compounds targeting PI3Kα for the treatment of triple-negative breast cancer, offering new ...

ETX-636 has a differentiated preclinical profile and the potential to deliver clinical benefit to patients with tumors harboring all forms of mutant PI3Kα. The ETX-636 preclinical data is being ...

“I am excited to join Totus Medicines and leverage my expertise in the biotech sector to support the advancement of our pipeline, which addresses critical unmet medical needs across multiple ...

Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small molecule precision oncology therapies, have announced a definitive ...

Report top-line results during the second half of 2025 from the APEX trial. APEX is a registration-directed, global, open-label trial of bezuclastinib in patients with Advanced Systemic Mastocytosis ...

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...